Hubert Muchalski

Dr. Hubert Muchalski

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2010 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
JJJeffrey N. Johnston
Jeffrey N. Johnston
HMHubert Muchalski
Hubert Muchalski
TTTimothy L. Troyer
Timothy L. Troyer

19 July 2007 in Macromolecules
Verified
Journal Article
Closed access
TCTeresa A. Croce
Teresa A. Croce
SHSharon K. Hamilton
Sharon K. Hamilton
MCMatthew L. Chen
Matthew L. Chen
HMHubert Muchalski
Hubert Muchalski
EHEva Harth
Eva Harth

1 January 2008 in Tetrahedron Letters
Verified
Journal Article
Closed access
RDR. Nathan Daniels
R. Nathan Daniels
KKKwangho Kim
Kwangho Kim
ELEvan P. Lebois
Evan P. Lebois
HMHubert Muchalski
Hubert Muchalski
MHMary Hughes
Mary Hughes
CLCraig W. Lindsley
Craig W. Lindsley

24 May 2020 in Molecules
Verified
Journal Article
Open access
PDF file
PRPravien Rajaram
Pravien Rajaram
ARAlyssa Rivera
Alyssa Rivera
KMKevin Muthima
Kevin Muthima
NONicholas Olveda
Nicholas Olveda
HMHubert Muchalski
Hubert Muchalski
QCQiao-Hong Chen
Qiao-Hong Chen
Enzalutamide is the first second-generation nonsteroidal androgen receptor (AR) antagonist with a strong binding affinity to AR. Most significantly, enzalutamide can prolong not only overall survival time and metastatic free survival time for patients with lethal castration-resistant prostate cancer (CRPC), but also castration-resistant free survival time for patients with castration-sensitive prostate cancer (CSPC). Enzalutamide has thus been approved by the US Food and Drug Administration (FDA) for the treatment of both metastatic (in 2012) and non-metastatic (in 2018) CRPC, as well as CSPC (2019). This is an inspiring drug discovery story created by an amazing interdisciplinary collaboration. Equally important, the successful clinical use of enzalutamide proves the notion that the second-generation AR antagonists can serve as hormonal therapeutics for three forms of advanced prostate cancer. This has been further verified by the recent FDA approval of the other two second-generation AR antagonists, apalutamide and darolutamide, for the treatment of prostate cancer. This review focuses on the rational design and discovery of these three second-generation AR antagonists, and then highlights their syntheses, clinical studies, and use. Strategies to overcome the resistance to the second-generation AR antagonists are also reviewed.

1 October 2008 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CNColleen M. Niswender
Colleen M. Niswender
ELEvan P. Lebois
Evan P. Lebois
QLQingwei Luo
Qingwei Luo
KKKwangho Kim
Kwangho Kim
HMHubert Muchalski
Hubert Muchalski
CLCraig W. Lindsley
Craig W. Lindsley

10 July 2009 in Macromolecules
Verified
Journal Article
Closed access
CAChinessa T. Adkins
Chinessa T. Adkins
HMHubert Muchalski
Hubert Muchalski
EHEva Harth
Eva Harth